Clinical Trial Update: Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chemotherapy in combination with an IDO inhibitor for metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IDO inhibitor (indoleamine 2,3-dioxygenase inhibitor)

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED